KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $86.5 million.

  • Esperion Therapeutics' Cash from Financing Activities rose 217.34% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year decrease of 26.70%. This contributed to the annual value of $86.5 million for FY2024, which is 71.39% up from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Cash from Financing Activities is $86.5 million, which was up 71.39% from $50.5 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Cash from Financing Activities peaked at $268.2 million during FY2021, and registered a low of $32.6 million during FY2022.
  • In the last 3 years, Esperion Therapeutics' Cash from Financing Activities had a median value of $50.5 million in 2023 and averaged $56.5 million.
  • In the last 5 years, Esperion Therapeutics' Cash from Financing Activities slumped by 87.84% in 2022 and then soared by 71.39% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Cash from Financing Activities stood at $201.7 million in 2020, then soared by 32.96% to $268.2 million in 2021, then slumped by 87.84% to $32.6 million in 2022, then skyrocketed by 54.76% to $50.5 million in 2023, then skyrocketed by 71.39% to $86.5 million in 2024.